Outcome of patients with preformed donor-specific antibodies following alemtuzumab induction and tacrolimus monotherapy. (scientific article)

A three-arm study comparing immediate tacrolimus therapy with antithymocyte globulin induction therapy followed by tacrolimus or cyclosporine A in adult renal transplant recipients

Q33347170

B-cell-depleting induction therapy and acute cellular rejection

Q34085081

Humoral theory of transplantation

Q35142603

Positive B-cell only flow cytometric crossmatch: implications for renal transplantation

Q37171317

Antibodies, isotypes and complement in allograft rejection.

Q37236978

Detecting and monitoring human leukocyte antigen-specific antibodies

Q37240375

Utility of the virtual crossmatch in solid organ transplantation

Q37594538

Back to the future: application of contemporary technology to long-standing questions about the clinical relevance of human leukocyte antigen-specific alloantibodies in renal transplantation

Q39979381

Banff 07 classification of renal allograft pathology: updates and future directions

Q40121163

B-cell tolerance in transplantation: is repertoire remodeling the answer?

Q42038591

Human monoclonal IgG isotypes differ in complement activating function at the level of C4 as well as C1q.

Q42939256

Clinical relevance of pretransplant donor-specific HLA antibodies detected by single-antigen flow-beads.

Q44092564

Campath-1H induction plus rapamycin monotherapy for renal transplantation: results of a pilot study.

Q44461489

Results from a human renal allograft tolerance trial evaluating the humanized CD52-specific monoclonal antibody alemtuzumab (CAMPATH-1H).

Q44514934

Detection of donor-specific antibodies using HLA-coated microspheres: another tool for kidney transplant risk stratification

Q44919347

Alloantibody levels and acute humoral rejection early after positive crossmatch kidney transplantation

Q46270876

Pretransplant donor-specific antibodies in cytotoxic negative crossmatch kidney transplants: are they relevant?

Q46630985

Alemtuzumab induction and sirolimus plus mycophenolate mofetil maintenance for CNI and steroid-free kidney transplant immunosuppression

Q46816120

T-lymphocyte alloresponses of Campath-1H-treated kidney transplant patients.

Q46900319

Five years of steroid sparing in renal transplantation with tacrolimus and mycophenolate mofetil

Q46900337

Skewing of pretransplant anti-HLA class I antibodies of immunoglobulin G isotype solely toward immunoglobulin G1 subclass is associated with poorer renal allograft survival

Q47331305

Clinical relevance of preformed HLA donor-specific antibodies in kidney transplantation

Q47641892

Significance of the positive crossmatch test in kidney transplantation

Q47800073

Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients. CHIB 201 International Study Group

Q47887130

HLA antibody identification with single antigen beads compared to conventional methods.

Q51303028

Donor-specific antibody levels and three generations of crossmatches to predict antibody-mediated rejection in kidney transplantation.

Q53310440

Renal transplantation in patients with pre-transplant donor-specific antibodies and negative flow cytometry crossmatches.

Q53528863

Single human leukocyte antigen flow cytometry beads for accurate identification of human leukocyte antigen antibody specificities.

Q53659700

P433

issue

P407